Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefapixant safety and efficacy in Japanese adults with chronic cough
NCT03696108Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2018
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of gefapixant in chronic cough (2 arms), sponsored by Merck & Co. Primary endpoints: Number of Participants Who Experienced at Least One Adverse Event (AE) up to 54 Weeks and Number of Participants Who Discontinued Study Drug Due to an AE up to 52 Weeks. Started Oct 2018; status: completed.
02
Drugs
gefapixant
03
Conditions
chronic cough
Beyond the preview
Go deeper on NCT03696108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03696108.